Table 1 Participant demographics
Demographics | Participants n = 10 |
|---|---|
Age at PANS onset. Years, median (range) | 7.1 (5.0 − 9.4) |
Sex | |
Boys | 4 (40%) |
Girls | 6 (60%) |
Age at baseline. Years, median (range) | 10.3 (6.3 − 16.1) |
Duration of illness. Years, mean (range) | 4.0 (0.3–9.2) |
Preexisting neurodevelopmental disorder | 4 (40%) |
Preexisting neurodevelopmental symptoms | 2 (20%) |
No neurodevelopmental disorder/symptoms | 4 (40%) |
Autoimmune diseases in first- or second-degree relatives | 7 (70%) |
Streptococcal infection preceding PANS onset | |
Verified/colonized | 2 (20%) |
Suspected | 3 (30%) |
CGI-S at baseline (Mean, SD) | 5.8 (0.42) |
PANS Scale (Mean, SD) | |
Symptom | 41.4 (5.30) |
Impairment | 39.8 (3.39) |
Total | 81.2 (7.83) |
Concomitant medication: | |
SSRI | 6 (60%) |
Antipsychotics | 3 (30%) |
ADHD medication | 3 (30%) |
Antibiotics | 3 (30%) |
NSAIDS | 2 (20%) |
Sleeping medication | 5 (50%) |
Antihistamines | 1 (10%) |